Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

Viral hepatitis is a leading cause of liver disease, liver cancer and liver transplant in the United States and is a focus of an annual national awareness campaign that occurs ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. The three main types—Hepatitis A, B, ...

In a very long-term follow-up cohort from childhood to adulthood in Taiwan, the scientists recruited 413 chronic HBV-infected patients who were followed from childhood to adulthood for a total of ...

Hepatitis B is a highly infectious liver disease caused by the Hepatitis B virus (HBV) and is primarily transmitted through infected blood, bodily fluids, or childbirth. Although many cases are acute ...

Hepatitis B is a serious liver infection that is caused by the hepatitis B virus (HBV). Around 254 million people live with hepatitis B, and 6000 people are newly infected with viral hepatitis each ...

With the exception of "Editorial use only" photos (which can only be used in editorial projects and can't be modified), the possibilities are limitless. Learn more about royalty-free images or view ...

the key source of replicating hepatitis B virus (HBV), and inactivating integrated HBV DNA in hepatocytes. “We are pleased to receive Fast Track designation from the FDA for PBGENE-HBV and ...

HBV=hepatitis ... B virus drug resistance. RAM=resistance-associated mutation. Evidence-based metrics are needed to link clinical and programme performance to HBVDR (panel 3). The WHO global viral ...